Despite the profitability miss, FY 23/24 guidance unchanged
09/02/24 -"CZM’s Q1 profitability fell short of expectations. Growth was once again led by Microsurgery, while Ophthalmology ended on a flat note. As expected, profitability was under pressure. Nonetheless, FY ..."
Pages
63
Language
English
Published on
09/02/24
You may also be interested by these reports :
19/08/26
S&N Q2/H1 26 print disappointed: revenue missed consensus, forcing management to cut FY26 revenue growth guidance to 4% from 6%, while Orthopaedics ...
19/08/26
With the release of the 1H results, we have slightly adjusted our expectations. We account for no revenue from pre-approved services in 2026, and ...
18/08/26
Coloplast delivered a mixed Q3 FY26: revenue beat consensus (+1.2%) but EBIT missed (-1%), with the margin declining for a third straight quarter. ...
18/08/26
SKAN delivered 22.2% net sales growth with a healthy order intake (book to bill ratio at 1.51x for 1H26) and a backlog growing 27.8% compared to the ...